Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAOA | P21397 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29890182 | 0.88 | ALDH1A1 (0.44) | ALDH1A1MAOAHPGDKDM4EGLA | |
| SCHEMBL7596891 | 0.88 | ALDH1A1 (0.44) | ALDH1A1MAOAHPGDKDM4EGLA | |
| SCHEMBL29733623 | 0.83 | CYP1A2 (0.50) | ALDH1A1MAOAHPGDKDM4EHSD17B10 | |
| SCHEMBL2537974 | 0.83 | CYP1A2 (0.50) | ALDH1A1MAOAHPGDKDM4EHSD17B10 | |
| SCHEMBL30092831 | 0.83 | CYP1A2 (0.50) | ALDH1A1MAOAHPGDKDM4EHSD17B10 | |
| SCHEMBL2537894 | 0.83 | CYP1A2 (0.50) | ALDH1A1MAOAHPGDKDM4EHSD17B10 | |
| SCHEMBL20668937 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAOAHPGDKDM4EGLA | |
| SCHEMBL12340285 | 0.79 | MCL1 (0.36) | ALDH1A1MAOAHPGDKDM4EGLA | |
| SCHEMBL20668933 | 0.78 | S100A4 (0.42) | ALDH1A1MAOAHPGDKDM4EGLA | |
| SCHEMBL22109147 | 0.78 | S100A4 (0.42) | ALDH1A1MAOAHPGDKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101925367-B | targeted radiation therapy | 鲁汶天主教大学 | 2017-05-31 | — | — | CN | claimed |
| US-8741262-B2 | Targeted radiotherapy | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-06-03 | — | — | US | claimed |
| EP-2219683-B1 | TARGETED RADIOTHERAPY | UNIV LEUVEN KATH (BE) | 2012-05-30 | — | — | EP | claimed |
| US-20110038795-A1 | TARGETED RADIOTHERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN K.U.LEUVEN R&D (BE) | 2011-02-17 | — | — | US | claimed |
| CN-101925367-A | targeted radiation therapy | UNIV LEUVEN KATH | 2010-12-22 | — | — | CN | claimed |
| EP-2219683-A2 | TARGETED RADIOTHERAPY | Katholieke Universiteit Leuven (BE) | 2010-08-25 | — | — | EP | claimed |
| US-20090274622-A1 | NECROSIS AVID TRACER AGENT | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-11-05 | — | — | US | claimed |
| WO-2009067767-A2 | TARGETED RADIOTHERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2009-06-04 | — | — | WO | claimed |
| EP-1651201-B1 | NECROSIS AVID TRACER AGENT | LEUVEN K U RES & DEV (BE) | 2008-01-02 | — | — | EP | claimed |
| US-20070122340-A1 | Necrosis avid tracer agent | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2007-05-31 | — | — | US | claimed |
| EP-4414354-A2 | SYSTEMS AND METHODS FOR PRODUCING SYNTHETIC HYPERICIN | Soligenix, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3423428-B1 | SYSTEMS AND METHODS FOR PRODUCING SYNTHETIC HYPERICIN | SOLIGENIX INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20190135724-A1 | Systems And Methods For Producing Synthetic Hypericin | SOLIGENIX, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3423428-A1 | SYSTEMS AND METHODS FOR PRODUCING SYNTHETIC HYPERICIN | Soligenix, Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180289670-A1 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2018-10-11 | — | — | US | disclosed |
| US-20070122340-A1 | Necrosis avid tracer agent | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2007-05-31 | — | — | US | disclosed |
| EP-1651201-A1 | NECROSIS AVID TRACER AGENT | K.U.Leuven Research & Development (BE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651201-A1 | NECROSIS AVID TRACER AGENT | K.U.Leuven Research & Development (BE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009423-A1 | NECROSIS AVID TRACER AGENT | K.U.LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009423-A1 | NECROSIS AVID TRACER AGENT | K.U.LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289670-A1 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER | MCL1, BAD, LPXN | ALDH1A1 869/4885MAOA 2165/4885HPGD 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.